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SUMMARY 
The therapeutic results obtained with Nitrazepam in 30 children with emotional disorders bet 
ween 4 and 14 years of age are reported, 17 children with habit disorders, 6 with behaviour, 5 with 
personality and 2 with Neurosis. Employing a flexible dosage schedule, a dose of 1/4 tablet to 1 tablet 
of 5 mg. Nitrozepam once to thrice daily was effective and safe. 24 of the 30 children (80%) showed 
recovery or marked improvement with over 50% fall in percentage reduction in total score based on 
assessing the target symptoms. 
Nitrazepam is a benzodiazepine de-
rivative, of which chlordiazepoxide, Dia-
zepam and Lorazepam are well known. 
By exerting a selective inhibitory effect 
confined specifically to the nervous structures 
concerned with the integration of emotional 
reactions (limbic system), Nitrazepam pre-
serves the balance between the "Wake 
System" and the Sensory and Autonomic 
Centres and induces sleep closely resembling 
physiological sleep in both onset and Course, 
Chemically, it is 1, 3-dihydro-7-nitro-5-
phenyl-2H-l ,4-benzodiayepine-2-one. The 
drug has been used mainly as a hypnotic 
(Le Riche et al., 1966) and considered as 
quite safe for this purpose. Matthew et 
al. (1969, 1972) commenting on the safety 
of Nitrazepam as a hypnotic observed that 
"the lethal dose in man remains unknown" 
and thus recommended it as the hypnotic 
of choice in patients at risk from over 
dosage. As no authenticated report of 
death from poisoning could be found even 
subsequent to his observations, the present 
study of its possible use in other emotional 
disorders, was prompted, especially in 
children, where the safety assumes consider-
able importance. 
MATERIAL AND METHOD 
Patients : The study was carried out 
on 30 patients who were selected from 
those attending the daily psychiatric Out-
patient department of Medical College 
S.S.G. Hospital, Baroda between April 
and September 1980. The first 30 patients 
who satisfied the criteria of selection com-
prised the material. The patients with 
known physical or neurological disorder, 
mental retardation and who were not 
likely to cooperate to make the trial reliable, 
were not included in the trial. The children 
ranged in age from 4 to 14 years with a 
mean age of 8.4 years and consisted of 21 
boys and 9 girls. The duration of emotional 
disorders varied from 3 days to 9 years 
(Mean 2.1 years). 
Treatment : The tablet provided for use 
in the trial contained 5 mg. of Nitrazepam. 
The initial dose was J or \ tablet depending 
upon age, once or twice daily which was 
gradually increased till desired effect was 
seen. A flexible dosage schedule was 
employed. The dosage was reduced if the 
severity of untoward symptoms warranted 
it. No additional medication was used in 
any case. 
Diagnosis : The emotional disorders were 
divided into disorders of personality (Timi-
dity, obstinacy, irritability, sensitiveness, 
shyness, etc.), behaviour (Truancy, Temper 
Tantrem, Food Fad, Cruelty, etc.), habit 
(Stammering, Enuresis, Nail-biting, Thumb-
sucking etc.) and Neuroses (anxiety, de-
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pression, obsession, phobia, hysteria). The 
grouping is for convenience of description, 
usually a patient had more than one symp-
tom (Table I). 
TABLE I—Information about patients (N=30) 
Age Range 
Mean Age 
Diagnosis 
Habit Disorders 
Behaviour Disorders 
Personality Disorders 
Neurotic Disorders 
Total 
: 4—14 Years 
: 8.4 Years 
: 17 
: 6 
: 5 
: 2 
: 30 
Assessment : In each child the target 
symptoms of emotional disorder, e.g. 
Stammering, learning disability etc., were 
noted and scored on a seven point scale, 
i.e., 0=absent; l=Very mild; 2=mild ; 
3=moderate ; 4=moderately severe ; 5 = 
Severe ; 6= extremely severe. The total 
score of all symptoms was considered as a 
parameter of the intensity of emotional 
disorder. 
The treatment was continued for six 
weeks and the patients were seen at weekly 
intervals when the target symptoms were 
scored and computed for percentage re-
duction in score. In addition global assess-
ment was made taking into account the 
assessment reported by parents/relatives 
besides the fall in score. Four arbitrary 
categories were adopted : Recovered, 
Markedly improved, Improved and Not 
improved. 
Assessment of Side Effects : Side-effects 
were recorded only if voluntarily com-
plained of by the patients/parents at the 
weekly interviews. Their intensity was 
recorded as mild, moderate and severe 
depending upon whether they were consi-
dered unimportant, sufficiently disturbing 
sometimes requiring reduction in dosage 
and incapacitating, requiring drastic reduc-
tion or discontinuation of the drug respec-
tively. 
Investigations : One third of the patients 
were subjected to Laboratory investigations 
before and after 6 weeks of treatment. They 
were haemogram, urinanalysis including 
microscopic examination and determination 
of S G O T and S G P T. 
RESULTS 
Table II shows the percentage reduc-
tion in total score and global evalutaions 
at successive weekly intervals. By either 
method there was no significant difference 
statistically (P<0.05), though they appear 
better by percentage score reduction than 
by global evaluation. A beneficial effect 
of the drug was apparent at the end of third 
or fourth week—24 of the 30 patients (80%) 
showed a satisfactory response, i.e. recovery 
to marked improvement. 
TABLE II—Response by percentage reduction and global assessment 
Number of Patients 
Percentage Reduction in Total Score (P) Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
Global Assessment (G) PGPGPGPGPGPG 
76 to 100 (Recovered) 
51 to 75 (Markedly Improved) 
26 to 50 (Improved) 
0 to 25 (Not Improved) 
0 
0 
2 
28 
0 
1 
1 
28 
1 
4 
4 
21 
1 
4 
6 
19 
3 
5 
7 
12 
5 
6 
8 
11 
7 
7 
10 
6 
7 
7 
11 
5 
10 
12 
4 
4 
11 
11 
4 
4 
15 
9 
2 
4 
14 
10 
2 
4 
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The usual effective dose was \ tab. thrice 
daily for children under the age of 8 and 
\ tab. thrice daily above that age, excepting 
in some where only one dose was necessary 
(Enuresis) or a larger dose of 1 tablet thrice 
daily (Personality disorder with irritability). 
Side-Effects : 14 patients complained 
of drowsiness, 2 severe, 8 moderate and 
4 mild, necessitating reduction of dosage 
in 5. No other side effect was complained 
of. 
DISCUSSION 
As it is inappropriate to use a fixed 
dosage in Clinical Phase I trials of anxiolytic 
drugs (W.H.O., 1967 ; Hollister 1970, 
F.D.A. 1974), a variable dosage regimen 
was employed in the present study. More-
over in actual clinical practice, drugs are 
used by individualising their doses. 
The recovery that was observed by the 
use of Nitrazepam in a remarkably high 
percentage of emotional disorders of child-
hood, raises the question of the mode in 
which the drug exerts this effect. It appears 
that the sedative hypnotic effect, well 
recognised for the drug cannot by itself 
explain the benefit derived. It is not 
unlikely that some other mechanism would 
explain the therapeutic efficacy, as no at-
tempt was made to modify or influence the 
environment and no social agencies took 
part in the treatment. The trial appears 
to have been successful in determining 
efficacy, clinical dosage, side-effects and 
safety. 
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